rimonabant Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
cannabinoid receptors antagonists 4150 168273-06-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SR141716A
  • rimonabant
  • acomplia
  • SR141716
A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY.
  • Molecular weight: 463.79
  • Formula: C22H21Cl3N4O
  • CLOGP: 6.47
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 50.16
  • ALOGS: -5.36
  • ROTB: 4

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 19, 2006 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Fear of eating 103.97 93.69 13 208 337 46685504

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC A08AX01 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Other antiobesity drugs
MeSH PA D019440 Anti-Obesity Agents
MeSH PA D063387 Cannabinoid Receptor Antagonists
MeSH PA D063385 Cannabinoid Receptor Modulators
MeSH PA D006728 Hormones
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:73416 cb1r antagonists
CHEBI has role CHEBI:74518 anti-obestic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Obesity indication 414916001 DOID:9970

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.58 acidic
pKa2 1.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cannabinoid receptor 1 GPCR ANTAGONIST Ki 9.72 CHEMBL DRUG LABEL
Acetylcholinesterase Enzyme IC50 4.60 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.55 CHEMBL
G-protein coupled receptor 55 GPCR EC50 5.70 CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.96 CHEMBL
N-arachidonyl glycine receptor GPCR IC50 5 CHEMBL
Cannabinoid receptor 2 GPCR Ki 6.43 CHEMBL
Cannabinoid receptor 1 GPCR Ki 8.82 CHEMBL
Cannabinoid receptor 1 GPCR Ki 9.51 CHEMBL

External reference:

IDSource
D05731 KEGG_DRUG
C2002731 UMLSCUI
CHEBI:34967 CHEBI
AY6 PDB_CHEM_ID
CHEMBL111 ChEMBL_ID
104850 PUBCHEM_CID
D000077285 MESH_DESCRIPTOR_UI
DB06155 DRUGBANK_ID
743 IUPHAR_LIGAND_ID
8029 INN_ID
RML78EN3XE UNII
011633 NDDF
422589005 SNOMEDCT_US
422794008 SNOMEDCT_US

Pharmaceutical products:

None